He is positive on Dr Reddy mainly because the company is going to benefit significantly in FY14 and FY15 from the new launches and at the same time the margins will also be higher. He does not expect any major surprise coming in Lupins' quarterly result.

Dr Reddy's Q1 net profit seen up 25% YoY to Rs 421 cr

The generic drugs maker's earnings will be boosted by strong growth in the US and Russian generics drugs market and better currency realisations.

Dr Reddys Lab Q1 net seen up 27.6% at Rs 450.3 cr: Emkay

Emkay Equity Advisory expects Dr Reddys Laboratories to report a 6.6 percent degrowth quarter-on-quarter (growth of 27.6 percent year-on-year) in net profit at Rs 450.3 crore.

Dr Reddys Lab Q1 PAT seen up 17.1% at Rs 290.7 cr: MOST

Motilal Oswal expects Dr Reddys Laboratories to report a 17.9 percent degrowth quarter-on-quarter (growth of 17.1 percent year-on-year) in net profit at Rs 290.7 crore.

Pharma cos likely to post 21% EBITDA growth in Q4: MOST

Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

Dr Reddy's Q3 revenue seen up 5% at Rs 2,913cr

Strong growth in US generic drug sales will continue to drive revenue growth for Dr Reddy's Laboratories. The pharma major will report its third quarter earnings on Thursday.

See pharma sector's Q3 topline to grow 22%: Motilal Oswal

Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher

Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.

See pharma sector's margins to dip 314 bps in 3QFY13: Angel

Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.

Q2 earnings: 9 stocks that beat estimates; 10 that didn't

With the September quarter earnings season just concluded, analysts are now taking stock of the numbers, and the hits and misses.

Dr Reddy's EBITDA up on product launches: CFO

Umang Vohra, executive VP and CFO, Dr Reddy‘s Laboratories explains to CNBC-TV18 that product launches have caused the surge in the pharma giant's quarterly EBITDA.

New products in mkt key to Dr Reddy's guidance: Centrum

Centrum Broking‘s Ranjit Kapadia explains to CNBC-TV18 that the performance of Dr Reddy's 18 new products is key to a revision of the management‘s guidance.

Dr Reddy's Labs Q2 PAT seen up 19% to Rs 365 cr

Dr Reddy's Laboratories' profit after tax is likely to go up by 19 percent year-on-year to Rs 365 crore in the second quarter of financial year 2012-13.

DRL Q2 revenues seen up 19% to Rs 2704 cr

Dr Reddy's Laboratories' profit after tax is likely to go up by 19 percent year-on-year to Rs 365 crore in the second quarter of financial year 2012-13.

Earnings watch: Which pharma co is in pink of its health?

In an interview to CNBC-TV18 Bino Pathiparampil of IIFL shared his expectation from various pharmaceutical companies ahead for their earnings.

Do Dr Reddy's, Hero Moto look attractive post Q1 results?

In an interview to CNBC-TV18 Dilip Bhat of Prabhudas Lilladher gave readings on the first quarter numbers of stocks across various sectors like Dr Reddy's, Hero Moto Corp and Bhat is bullish on both these stocks.

DRL Q1 revenues seen up 33% YoY to Rs 2,632 cr

Pharma major Dr Reddy's Labs (DRL) is going to declare its results for the April-June quarter today. Analysts on average expect the company to mirror last quarter's performance.

Dr Reddy's Labs' Q1 PAT likely to grow 34% to Rs 353 cr

Pharma major Dr Reddy's Labs (DRL) is going to declare its results for the April-June quarter today. Analysts on average expect the company to mirror last quarter's performance.

Adj PAT of healthcare sector likely to grow 11% YoY: MOSt

Motilal Oswal expects topline growth of 22% YoY for their Healthcare universe (excluding one-offs), with robust EBITDA growth of 35% YoY. Adjusted PAT is likely to grow 11% YoY, says Motilal Oswal.

US, Russia & API boost Dr Reddy's as busy year looms

GV Prasad VC & CEO, Dr Reddy Laboratories explains to CNBC-TV18 that the reason for company‘s good performance for the quarter is the robust growth in the US, Russia and the API business

Dr Reddy's Labs Q4 PAT seen up 28% at Rs 429 cr

Pharmaceutical company Dr Reddy's Labs is expected to report a growth of 28% year-on-year in its profit after tax of Rs 429 crore for the fourth quarter of FY12, according to CNBC-TV18 poll.

Dr Reddy's Labs Q4 EBITDA seen up 85% at Rs 712 cr

Pharmaceutical company Dr Reddy's Labs is expected to report a growth of 28% year-on-year in its profit after tax of Rs 429 crore for the fourth quarter of FY12, according to CNBC-TV18 poll.

See strong performance by pharma in Mar quarter: KR Choksey

According to the report on earnings preview for the quarter ended March 2012, KR Choksey expects the pharma sector will show strong performance in the domestic pharmaceuticals market mainly due to recovery in Indian pharma market.

Have many significant product launches lined up: Dr Reddy's

Dr Reddy’s also has slew of significant new launches lined-up ahead. It would also be launching a biosimilar product every year beginning with the Indian market. These products are expected to drive company's near-term growth.

Dr Reddy's Labs PAT likely to soar 55.5% in Q3

Pharmaceutial firm Dr Reddy's Laboratories is expected to report a profit after tax of Rs 425 crore in the third quarter of FY12, a massive growth of 55.5% as compared to Rs 273 crore in a year ago quarter.